Management of treatment-emergent peripheral neuropathy in multiple myeloma

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

(2011) P. Moreau et al.   BLOOD

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma

(2011) David C. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

(2011) Irene M Ghobrial et al.   LANCET ONCOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland

(2011) I. Hrusovsky et al.   ONCOLOGY

Genetic variation associated with bortezomib-induced peripheral neuropathy

(2011) Reyna Favis et al.   Pharmacogenetics and Genomics

Balancing act for elderly myeloma

(2010) A. Palumbo   BLOOD

Sequence variation at multiple loci influences red cell hemoglobin concentration

(2010) L. L. Peters et al.   BLOOD

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

(2010) C. B. Reeder et al.   BLOOD

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

(2010) J. A. Zonder et al.   BLOOD

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

(2010) S. Kumar et al.   BLOOD

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition

(2010) Marianne S. Poruchynsky et al.   CELL CYCLE

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

(2010) Lawrence R. Dick et al.   DRUG DISCOVERY TODAY

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

(2010) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice

(2010) Jordi Bruna et al.   EXPERIMENTAL NEUROLOGY

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

(2010) B. Mohty et al.   HAEMATOLOGICA

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

(2010) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients

(2010) Roser Velasco et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

(2010) María-Victoria Mateos et al.   LANCET ONCOLOGY

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

(2010) Annemiek Broyl et al.   LANCET ONCOLOGY

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

(2010) Michel Delforge et al.   LANCET ONCOLOGY

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

(2010) M Q Lacy et al.   LEUKEMIA

A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA

(2010) Debra L. Barton et al.   SUPPORTIVE CARE IN CANCER

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

(2009) F. Gay et al.   BLOOD

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-  and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response

(2009) M. Remke et al.   BLOOD

Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia

(2009) D. C. Rees et al.   BLOOD

Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration

(2009) M. C. Ghosh et al.   BLOOD

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

(2009) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

(2009) Cyrille Hulin et al.   JOURNAL OF CLINICAL ONCOLOGY

Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma

(2009) Michele Cavo et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

(2009) Vinay Chaudhry et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study

(2009)   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

(2008) H. Ludwig et al.   BLOOD

Thalidomide for treatment of multiple myeloma: 10 years later

(2008) A. Palumbo et al.   BLOOD

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

(2008) A. Palumbo et al.   BLOOD

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

(2008) Rakesh Popat et al.   BRITISH JOURNAL OF HAEMATOLOGY

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

(2008) Joseph R. Mikhael et al.   BRITISH JOURNAL OF HAEMATOLOGY

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

(2008) Marie von Lilienfeld-Toal et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

(2008) H. M. Lokhorst et al.   HAEMATOLOGICA

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

(2008) S. Vincent Rajkumar et al.   JOURNAL OF CLINICAL ONCOLOGY

From Bench to Bedside: A Case of Rapid Reversal of Bortezomib-Induced Neuropathic Pain by the TRPM8 Activator, Menthol

(2008) Leslie A. Colvin et al.   JOURNAL OF CLINICAL ONCOLOGY

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

(2008) M Pineda-Roman et al.   LEUKEMIA

Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro

(2007) V CSIZMADIA   NEUROTOXICOLOGY